Kaye, Donald
April 2004
Clinical Infectious Diseases;4/1/2004, Vol. 38 Issue 7, piv
Academic Journal
Reports a new class of antiretroviral drugs that prevent HIV from infecting cells. Advantages of the drug; Details of SCH-D, an antagonist of the CCR5 coreceptor, as provided by Mark Laughlin and colleagues of Schering-Plough Research Institute in Kenilworth, New Jersey at the 11th Annual Retrovirus Conference; Submission of preliminary data for BMS-488043 by Bristol-Myers Squibb.


Related Articles

  • South African government seeks reassurances on AIDS initiative. Cherry, Michael // Nature;6/17/1999, Vol. 399 Issue 6737, p624 

    Reports on the confirmation from South Africa's Minister of Health, Nkosazana Zuma, that offers from the United States pharmaceutical company Bristol-Myers Squibb (BMS) to donate money toward fighting AIDS were not rejected. Details of the initiative; Changes that South Africa wants before the...

  • HIV-25 YEARS LATER. Belden, Heidi // Drug Topics;11/20/2006, Vol. 150 Issue 22, p36 

    The article focuses on various developments related to AIDS prevention in the United States as of November 20, 2006. One important development was the Food and Drug Administration's approval of Tibotec's darunavir Prezista for marketing in June 2006. Another development was the introduction of...

  • Infectious Diseases News Round-up.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p30 

    Reports on news and developments concerning pharmaceutical companies focusing on treatment of infectious diseases. AIDS Healthcare Foundation and Abbott Laboratories' collaboration on HIV/AIDS testing, prevention and treatment programs in the United States and Africa; Bristol-Myers Squibb Co.'s...

  • Taking Biomarkers into the Clinic. Shaffer, Catherine // Drug Discovery & Development;Jun2006, Vol. 9 Issue 6, p60 

    The article discusses the utilization of biomarkers in clinical research and development. Joseph Ahearn, co-director of the Lupus Center of Excellence at the University of Pittsburgh introduced a new set of biomarkers for monitoring the progression of lupus. Bristol-Myers Squibb is using genetic...

  • Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals. Phelps, Benjamin R.; Hathcock, Sarah J.; Werdenberg, Jennifer; Schutze, Gordon E. // Journal of the International AIDS Society;2010, Vol. 13 Issue 1, p1 

    Background: Lack of adherence to antiretroviral medications is one of the key challenges for paediatric HIV care and treatment programmes. There are few hands-on opportunities for healthcare workers to gain awareness of the psychosocial and logistic challenges that caregivers face when...

  • Diseases in the Third World Challenge Manufacturers. Wechsler, Jill // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p36 

    Focuses on challenges in manufacturing fixed-dose combination drugs for AIDS patients in developing countries. Need for expansion of manufacturing operations to meet demands for AIDS drugs; Meeting of worldwide regulatory standards; Problems of Bristol-Myers Squibb in meeting demand for...

  • Bristol-Myers Squibb and the Medicines Patent Pool – An Unlikely Marriage? Chu, Rachel // European Journal of Risk Regulation;2014, Vol. 5 Issue 1, p68 

    The article reports on the agreement of pharmaceutical Bristol-Myers Squibb with the Medicines Patent Pool (MPP) to license atazanavir, an antiretroviral (AVR) drug. It says that the agreement adds an important compound to the arsenal of treatments for HIV/AIDS and strengthen the defence of...

  • Welcoming Atripla. McManus, Michael // Advocate;8/29/2006, Issue 969, p47 

    The article reports on the approval of the antiretroviral HIV/AIDS drug Atripla from Bristol-Mayers Squibb by the U.S. Food and Drug Administration. When the first antiretroviral HIV/AIDS drugs were approved by the Food and Drug Administration 10 years ago, many patients were taking more than 20...

  • Anticipating the once-a-day pill. Adams, Bob // Advocate;4/11/2006, Issue 960, p48 

    The article announces the availability of a new daily anti-HIV pill later this 2006. In January, drugmakers Bristol-Myers Squibb (BMS) and Gilead Sciences announced that they have successfully layered Sustiva of BMS into a single pill with Gilead's Truvada, which itself is a combination of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics